{"filing":{"accession_number":"0001178913-26-002900","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"zk2635400.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002900/zk2635400.htm"},"events":[{"id":8997,"run_id":7898,"accession_number":"0001178913-26-002900","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Silexion announced a 1-for-10 reverse share split effective May 28, 2026, following shareholder approval on May 5, 2026. While reverse splits are routine capital structure adjustments, this disclosure is material because it affects the total mix of information available to investors regarding share ownership, voting power, and trading mechanics. The event does not fit the more specific categories (not a dilutive issuance, not a restatement, not an impairment), making \"other_material\" the appropriate classification.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1467,"accession_number":"0001178913-26-002900","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Silexion announced a 1-for-10 reverse share split effective May 28, 2026, following shareholder approval on May 5, 2026. While reverse splits are routine capital structure adjustments, this disclosure is material because it affects the total mix of information available to investors regarding share ownership, voting power, and trading mechanics. The event does not fit the more specific categories (not a dilutive issuance, not a restatement, not an impairment), making \"other_material\" the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:09:32.519357+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1467,"accession_number":"0001178913-26-002900","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Silexion announced a 1-for-10 reverse share split effective May 28, 2026, following shareholder approval on May 5, 2026. While reverse splits are routine capital structure adjustments, this disclosure is material because it affects the total mix of information available to investors regarding share ownership, voting power, and trading mechanics. The event does not fit the more specific categories (not a dilutive issuance, not a restatement, not an impairment), making \"other_material\" the appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:09:32.519357+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-05-26"}]}